Seeking Alpha

wired4acure

wired4acure
Send Message
View as an RSS Feed
View wired4acure's Comments BY TICKER:
Latest  |  Highest rated
  • Another Day, Another Major Shale Discovery [View article]
    considering how much money we pay the in FEDERAL taxes- we should be able to demand a national energy strategy- all these studies and whining about fossil fuels vs alternative energy is just noise- Like the mess the FEDS have made of health care we spend spend spend and get dribble from Washington DC and the various FEDERAL agencies that should be held accountable. Boon Pickens tried to goad them into a real policy and yet here we sit 5+ years and Obama and his handmaidens and stooges have yet to articulate a real way ahead to secure our national survival with an intelligent plan to address energy consumption, export, and reserve management. SHAME on them all. NOT one more tax dollar dime for alternative energy until they address the whole of our engery needs and resources.
    Mar 3 10:37 AM | 6 Likes Like |Link to Comment
  • Cytori Therapeutics: Global Patient Stem Cell Demand Builds, Important Short-Term Catalysts Ahead [View article]
    The stakes are high- commercial interests in other solutions have huge influence on FDA-

    The end the mess the health industry in the US finds itself in will be what turns the tide - given that we spend more than another modern society on medicine and do not have survival statistics that back up that investment means something has to give. Cytori offers the potential for many cost effective treatments for many different medical conditions- ignoring the potential will only cause the world medical community to offer opportunities for more offshore clinics- it is clearly already happening. Once results are publicized and success is in the mainstream media a major FDA capitulation will be forced- especially if more and more folks are forced to pay huge deductibles- One might as well go overseas for cheaper more effective course of therapies than be forced to submit to the insurance industry choices and FDA 's "safe" 20th Century treatments
    Feb 13 03:26 PM | 1 Like Like |Link to Comment
  • Dendreon Announces Presentation of PROVENGE┬« (sipuleucel-T) Data at the 2014 Genitourinary Cancer Symposium (ASCO GU) [View article]
    Appears as though there are going to be many more patients for whom Provenge is an appropriate treatment- with limited side effects
    Feb 5 09:20 AM | Likes Like |Link to Comment
  • Dendreon Is A Steal Compared To New Drug Development [View article]
    thanks for the well articulated argument in favor of holding this for the eventual turn-around. Odds seem to be in favor of longs, but that has been the carrot a long time. Now we need to see some follow-thru and execution from Dendreon management.
    Dec 18 02:19 PM | 4 Likes Like |Link to Comment
  • Cytori Therapeutics $531,000,000 Agreement - Money Talks [View article]
    Well done Wall Street Titan , my only comment is good for us that this market in Asia and Australia because of the added advantage of being beyond the Obamacara battle. Lets see the technology proven in these emerging economies. See if this does not force FDA to catch-up and be pressured by US medical interests losing business to Medical Tourism. Medical solutions at a discount with a vacation as a bonus have a big allure to Europeans - can the US patient be far behind?
    Nov 6 01:04 PM | 5 Likes Like |Link to Comment
  • Wedbush says Dendreon deal makes little sense for Big Pharma [View news story]
    no vision + no imagination = analyst with short position
    Oct 28 01:12 PM | Likes Like |Link to Comment
  • Dendreon to pursue sale: Bloomberg [View news story]
    not just a one trick pony- future applications based on the use of their platform have big future. Personalized medicine is going to me the medical rule in the near future-

    Gold's loudly stated strategy to go it alone and shun all partners made them a target for BP. This an other poor management decisions like over building hurt the stock as it gained initial FDA approval. The overhead and marketing issues have been addressed. The science and patents are most certainly marketable and coveted. A loud announcement of availability will trigger a positive response with European and international audiences. Not all suitors are apt to cut their noses off to save face on this one. GLTAL
    Oct 28 08:42 AM | 3 Likes Like |Link to Comment
  • Dendreon: Time To Prove Itself Or Perish [View article]
    The cheerleaders for a partner or bust maybe the same hedge funds who are betting on BP- The lower the price at acquisition the better for them on both ends... the guys in the know are hoping that the scramble for the exit doors will crush retail shorts - as the unwind the short positions the announcement gets closer...

    Bill it Sounds to me like you are trying to flush management out if their silence in the hopes they are actually working for a higher SP vs. a deal at any price. I have to think that the R&D investment supports a real effort to raise their bargaining power with new pipeline product or solid evidence of broaden application- nobody on these boards knows the real truth- we will have wait and see-
    Oct 3 10:32 AM | Likes Like |Link to Comment
  • Dendreon: Looking For Spare Change In The Cushions [View article]
    IMHO the timeline to profit can be shortened dramatically by good news and positive results from the patient population. What is needed is better means of evaluating the anticipated OS of patients already treated. What if any light do readers have on the progress made to find more effective biomarkers.

    And if pushed why wouldn't Dendreon sell rights to patents- or barter these in a partner deal? Further dilution will have a negative effect on share price and I think current directors have to be working to avoid this for themselves if not for the rest of us as shareholders.

    Excerpt from Ted Cohen article:

    "Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. (C13)
    Mehmet Hepgur - University of Southern California, Norris Comprehensive Cancer Center

    The investigators prospectively collected CTC, LDH, and inflammatory markers as part of an audit to investigate changes after sipuleucel-T treatment compared to baseline. Men with CRPC had blood drawn routinely before and after treatment with Provenge. Conclusions: "We found that CTC counts can decline after (Provenge) treatment, including conversion from unfavorable to favorable range, and can change independently of PSA. Correlation of CTCs with outcomes in a prospective study is warranted to explore this as a potential biomarker.""
    Sep 30 12:51 PM | 2 Likes Like |Link to Comment
  • Dendreon: Looking For Spare Change In The Cushions [View article]
    I notice you were careful not to mention the direct competitors by name. So let me do it for you: Johnson & Johnson's drug Zytiga , Medivation Inc. and Astellas Pharma's drug candidate MDV3100. Under full disclosure do you, Small Cap Strategist web log, Crystal Equity Research or its affiliates have a beneficial interest in these companies? And there are other solutions for Dendreon, which include restructuring their current debt and finding the right partner. 100% downside for company with an FDA approved treatment for cancer and a number of related patents is not without other options. Not to mention the possibility of openting this treatment for early stage prostate patients.
    Sep 28 02:23 PM | 7 Likes Like |Link to Comment
  • Cytori Therapeutics - Independent Study On Scleroderma Shows Great Results [View article]
    Better than this study are the implications for finding a way to treat the other 80 autoimmune disorders which include:
    Addison's disease
    Celiac disease - sprue (gluten-sensitive enteropathy)
    Dermatomyositis
    Graves disease
    Hashimoto's thyroiditis
    Multiple sclerosis
    Myasthenia gravis
    Pernicious anemia
    Reactive arthritis
    Rheumatoid arthritis
    Sjogren syndrome
    Systemic lupus erythematosus
    Type I diabetes
    Sep 22 02:25 PM | Likes Like |Link to Comment
  • Organovo May Be Big Pharma's Salvation [View article]
    Great well reasoned article - thanks for your research effort and generosity in sharing it.- The rising R&D costs are enough to make this stock look very interesting. The Roche collaboration is promising. Hope Dendreon and other cancer vaccine BIOtechs benefit sooner than later and grow their pipelines. A cure or non lethal treatment for cancer is long overdue.
    Sep 17 05:34 PM | 1 Like Like |Link to Comment
  • Terminal Diagnosis: Despite What You May Have Heard, Dendreon Is A 'Dead Company Walking' [View article]
    If the hedge funds are so confident and made so much money shorting already...why not just cash in. This technology using the immune system is just taking off. BP is buying in and while not yet profitable DNDN is generating income. Right or wrong backing this effort is about something bigger than the almighty buck. GLTALs and cancer patients. And pray for real SEC reform
    Aug 27 05:14 AM | 2 Likes Like |Link to Comment
  • 5 Names That Should Raise Funds Through Equity Now [View article]
    Hedge fund shorts writing advice articles to scare all retail out of dndn are so transparent. They never mention r&d investment, future pipeline, or other factors, and constantly bash management. If a story is so one sided .... Why the need to lie? If they are so comfortable with the bet they laid down don't they have better things to do? The whole hedge fund method, rules, secrecy, and slant of Wall Street has nearly killed the retail market while the inept regulator sit there with their thumbs stuck up...
    Aug 27 04:47 AM | 1 Like Like |Link to Comment
  • Dendreon Corporation Management Discusses Q2 2013 Results (Webcast) [View article]
    at least this biotech has a product that is in production and generating revenue. Wish they would elaborate on European market and go green on schedule.
    Aug 8 05:34 PM | Likes Like |Link to Comment
COMMENTS STATS
31 Comments
49 Likes